Watch Demo

Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
  • Publish Date:May 2023

  • Number of Pages:97

  • Report ID:6465088

  • Format:PDF

  • Publisher:GlobalData

$ 3495

Summary

Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary
This reports provides a data-driven overview of the current and future competitive landscape in PsA therapeutics.

- There will be more than 6 million prevalent cases of PsA in 2023 in the 16 countries covered in epidemiology forecast.
- There are 14 leading marketed drugs for the treatment of PsA, Janssen is the key player in the PsA landscape with five marketed products.
- R&D activity in PsA is robust globally, with three products in the pre-registration phase in the US, Japan, and EU, and 14 products in Phase III development across the global markets.
- Commercial sponsors dominate clinical trial development in PsA, with the US emerging as the key country for conducting Phase III trials in PsA.
- During the past 12 months, three mergers and acquisitions, and five strategic alliances deal involving companies developing PsA assets have been completed.

Scope
PsA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the PsA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of contents

1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations

2 Key Findings

3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview...

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.